Scimed
This article was originally published in The Gray Sheet
Executive Summary
Receives approval to market the Maverick, the firm's "first peripheral [percutaneous transluminal angioplasty] catheter designed for large blood vessels," Dale Spencer, Scimed president and CEO, reported at the June 15-17 Piper Jaffray conference in Minneapolis. The firm received 510(k) clearance to market the device on May 20. Scimed says that the catheter is suitable for larger vessels located above the knee, as opposed to the firm's Viper, which is indicated for lower-leg vessels. The firm is waiting to accumulate a more broad product line for peripheral vessels before it adopts a "targeted" marketing approach for the Maverick, which sells for between $100 and $200. Scimed also plans to begin clinical trials later this year for a non-PTCA intravascular therapeutic catheter, Spencer said.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.